Zai Lab Net Income Over Time

ZLAB Stock  USD 18.10  0.63  3.61%   
Historical fundamentals for Zai Lab provide evidence for valuation and risk assumptions. This module compares long-run financial quality trends for Zai Lab.
For Zai Lab, Zai Lab Performance and Zai Lab Correlation supply complementary context.
For information on how to trade Zai Stock refer to our How to Invest in Zai Lab guide.As of now, Net Loss is anticipated to decline to approximately -184.3 M. In addition to that, The current year's Net Loss is projected to rise to approximately -379 M.
 Earnings Share
-1.60
 Revenue Per Share
4.201
 Quarterly Revenue Growth
0.17
 Return On Assets
-0.12
 Return On Equity
-0.23
The market value of Zai Lab is measured differently than book value, which reflects Zai accounting equity. The dataset reflects available inputs without directional implication.
Value and price for Zai Lab may converge over time but can differ substantially in any given period. Exchange pricing for Zai Lab reflects real-time supply and demand across active participants.
Specify up to 10 symbols:

Peer Comparison: Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Zai Lab financial statement analysis. It represents the amount of money remaining after all of Zai Lab operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Compare Zai Lab and related stocks such as Legend Biotech Corp, Disc Medicine, and Ascentage Pharma Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
20102011201220132014201520162017201820192020202120222023202420252026
LEGN9.4 M9.4 M9.4 M9.4 M9.4 M9.4 M9.4 M9.4 M-2.8 M-101.6 M-266.4 M-403.6 M-446.3 M-518.3 M-177 M-297.6 M-312.5 M
IRON-40.8 M-40.8 M-40.8 M-40.8 M-40.8 M-40.8 M-40.8 M-40.8 M-40.8 M-40.8 M-40.8 M-36 M-46.1 M-76.4 M-109.4 M-212.2 M-201.6 M
AAPG-107.8 M-107.8 M-107.8 M-107.8 M-107.8 M-107.8 M-107.8 M-118.5 M-345.3 M-1.5 B-677.6 M-782.4 M-882.9 M-925.6 M-405.4 M-364.9 M-383.1 M
SRRK-16.2 M-16.2 M-16.2 M-16.2 M-16.2 M-16.2 M-16.2 M-25 M-49.3 M-49.7 M-85 M-131.8 M-131.6 M-165.8 M-246.3 M-377.9 M-359 M
IDYA-11.9 M-11.9 M-11.9 M-11.9 M-11.9 M-11.9 M-11.9 M-11.9 M-34.3 M-38.4 M-32.3 M-47.5 M-54.8 M-113 M-274.5 M-113.7 M-119.4 M
CNTA-5.3 M-5.3 M-5.3 M-5.3 M-5.3 M-5.3 M-5.3 M-5.3 M-5.3 M-5.3 M-10.7 M-381.9 M-216.2 M-151.1 M-235.8 M-212.2 M-222.8 M
XENE-12 M-12 M-4.3 M12 M13 M-15.8 M-23 M-30.7 M-34.5 M-41.6 M-28.8 M-78.9 M-125.4 M-182.4 M-234.3 M-345.9 M-328.6 M
TARS-1.3 M-1.3 M-1.3 M-1.3 M-1.3 M-1.3 M-1.3 M-1.3 M-1.3 M-4.7 M-26.8 M-13.8 M-62.1 M-135.9 M-115.6 M-66.4 M-69.7 M
APGE-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-39.8 M-84 M-182.1 M-255.8 M-243.1 M

My Equities

My Current Equities and Potential Positions

Zai Lab
ZLAB
ClassificationCancer Fighters
Business AddressBuilding B, Pudong,
ExchangeNASDAQ Exchange
USD 18.1

More Resources for Zai Stock Analysis

A baseline understanding of Zai Lab is formed through its financial statements and trends. These metrics are based on Zai Lab's reported financial results.